

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE SIX MONTHS ENDED 30 JUNE 2021

On 14 July 2021, Dong-E-E-Jiao released its results estimate for the six months ended 30 June 2021.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 8.86% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.14% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 21.96% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 14 July 2021, Dong-E-E-Jiao released its results estimate for the six months ended 30 June 2021. In which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the six months ended 30 June 2021 would range from RMB128.34 million to RMB164.57 million, representing an increase between 253% and 296% as compared to the net loss of RMB84.02 million for the same period last year (the “**Dong-E-E-Jiao Results Estimate**”).

The main reasons for the change in results are set forth as follows:

1. Adhering to the consumer-centric principle, Dong-E-E-Jiao is committed to digital transformation, enriching product matrix, promoting organizational reform, improving organizational efficiency and unleashing organizational vitality, thereby achieving positive market growth with new growth logic.
2. In the future, Dong-E-E-Jiao will continue to improve the quality of customer operation, accelerate digital transformation and business model upgrade, strengthen the transformation and innovation of scientific research achievements, promote brand specialization and differentiation, deeply promote reshaping in value, business, organizational and spiritual aspects, and strive to become a leader in the Chinese nutritional health trusted by consumers and a role model for the high-quality development of the Chinese medicine enterprises.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For the details of financial data, those to be disclosed in the interim report for the six months ended 30 June 2021 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Wang Chuncheng
Chairman

Hong Kong, 15 July 2021

As at the date of this announcement, the Board comprises Mr. Wang Chuncheng as chairman and non-executive Director, Mr. Han Yuewei, Mr. Li Xiangming and Mdm. Weng Jingwen as executive Directors, Mr. Yu Zhongliang, Mdm. Guo Wei, Mr. Hou Bo and Mr. Qing Mei Ping Cuo as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.